- Trials with a EudraCT protocol (13)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (2)
13 result(s) found for: Plasmin.
Displaying page 1 of 1.
EudraCT Number: 2006-002447-81 | Sponsor Protocol Number: 050003 | Start Date*: 2007-04-12 | |||||||||||
Sponsor Name:Talecris Biotherapeutics, Inc | |||||||||||||
Full Title: A Sequential Phase I/II Dose Escalation and Dose Selection Safety Study of Regional Intra-thrombus Plasmin (Human) Infusion In Acute Lower Extremity Native Artery or Bypass Graft Occlusion | |||||||||||||
Medical condition: Acute Lower Extremity Native Artery or Bypass Graft Occlusion | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) DE (Completed) CZ (Completed) BG (Completed) HU (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2010-019760-36 | Sponsor Protocol Number: T05018-2004 | Start Date*: 2010-11-22 | |||||||||||
Sponsor Name:Grifols Therapeutics, Incorporated | |||||||||||||
Full Title: A Phase 2, Randomized, Open-label (with Blinded Plasminogen Activator and Placebo Control Groups) Study to Evaluate the Effects of Different Intra-thrombus Infusion Regimens of Plasmin (Human) Comp... | |||||||||||||
Medical condition: acute peripheral arterial occlusion | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: SK (Completed) HU (Prematurely Ended) DE (Prematurely Ended) BE (Completed) ES (Prematurely Ended) CZ (Completed) BG (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2009-012086-66 | Sponsor Protocol Number: T05018-1001 | Start Date*: 2009-12-01 | |||||||||||
Sponsor Name:Grifols Inc | |||||||||||||
Full Title: A Phase 1/2a, Open Label, Dose Escalation, Safety Study of Intra-thrombus Plasmin (Human) Administration in Acute, Middle Cerebral Artery, Ischemic Stroke | |||||||||||||
Medical condition: Thrombus in acute ischemic stroke of the middle cerebral artery | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) GB (Completed) FR (Completed) SK (Completed) AT (Completed) | |||||||||||||
Trial results: Removed from public view |
EudraCT Number: 2015-001946-26 | Sponsor Protocol Number: AMITNED | Start Date*: 2016-01-19 |
Sponsor Name:Aarhus University Hospital | ||
Full Title: Amilorid treatment of nephrotic edema | ||
Medical condition: Childhood idiopathic nephrotic syndrome (NS) | ||
Disease: | ||
Population Age: Infants and toddlers, Children, Under 18 | Gender: Male, Female | |
Trial protocol: DK (Prematurely Ended) | ||
Trial results: View results |
EudraCT Number: 2017-002760-41 | Sponsor Protocol Number: CL2-RTCCAR-001 | Start Date*: 2017-09-18 | |||||||||||
Sponsor Name:institute de Recherches Internacionales Servier (promotor internacional) | |||||||||||||
Full Title: Assessment of Active Thrombin-Activatable Fibrinolysis Inhibitor (TAFIa) plasma kinetics in Patients at acute stage of Ischemic Stroke: Prospective, Multicentre, Open, Non-randomised, Biomarker Study | |||||||||||||
Medical condition: Acute Ischemic Stroke | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2007-000631-25 | Sponsor Protocol Number: 2007-000631-25 | Start Date*: 2010-06-08 | |||||||||||
Sponsor Name:KAROLINSKA INSTITUTET | |||||||||||||
Full Title: THE ANTITTHROMBOTIC EFFECTS OF DOXAZOSIN AND RAMIPRIL IN ESSENTIAL HYPERTENSION | |||||||||||||
Medical condition: ESSENTIAL HYPERTENSION | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: SE (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2010-024377-40 | Sponsor Protocol Number: TPA-ALI | Start Date*: 2011-06-29 |
Sponsor Name:Medizinische Universität Wien, UniKlinik für Klinische Pharmakologie | ||
Full Title: A randomized phase II pilot - trial, examining the safety, pharmacokinetics, pharmacodynamics, and clinical efficacy of escalating doses of alteplase in patients with acute lung injury / acute resp... | ||
Medical condition: acute lung injury, acute respiratory distress syndrom, severe pneumonia | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: AT (Prematurely Ended) | ||
Trial results: View results |
EudraCT Number: 2021-001381-38 | Sponsor Protocol Number: 1 | Start Date*: 2021-08-30 | |||||||||||
Sponsor Name:Plastikkirurgisk og brystkirurgisk afdeling, Region Sjælland | |||||||||||||
Full Title: Topical use of tranexamic acid for optimisation of wound healing in a novel, acute wound model | |||||||||||||
Medical condition: Immunomodulation of postoperative inflammatory reactions and thereby reduction of wound fluid production and improved healing by topical administration of tranexamic acid. | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: DK (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-005592-12 | Sponsor Protocol Number: 76873 | Start Date*: 2021-08-30 | |||||||||||
Sponsor Name:Plastikkirurgisk og brystkirurgisk afdeling, Region Sjælland | |||||||||||||
Full Title: The effect of tranexamic acid on seroma formation after mastectomies | |||||||||||||
Medical condition: Immunomodulation of postoperative inflammatory reactions and thereby reduction of wound seroma by topical administration of tranexamic acid. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DK (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2021-000939-31 | Sponsor Protocol Number: JDS_2021_5 | Start Date*: 2021-11-02 |
Sponsor Name:Hôpital Fondation A. de Rothschild / Service de recherche clinique | ||
Full Title: Efficacy of dornase alfa (Pulmozyme®) on arterial recanalization in post-thrombectomy angiography in patients managed for ischemic stroke by thrombolysis and eligible for thrombectomy: a monocentri... | ||
Medical condition: cerebral thrombectomy | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: FR (Trial now transitioned) | ||
Trial results: (No results available) |
EudraCT Number: 2019-004118-33 | Sponsor Protocol Number: PATCH_Trauma | Start Date*: 2020-11-03 | |||||||||||
Sponsor Name:Universität Witten/Herdecke | |||||||||||||
Full Title: A multi-centre randomised, double-blind, placebo-controlled trial of pre-hospital treatment with tranexamic acid for severely injured patients at risk of acute traumatic coagulopathy. | |||||||||||||
Medical condition: Trauma patients with risk for acute traumatic Coagulopathy and Hemorrhage | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2014-001513-35 | Sponsor Protocol Number: | Start Date*: 2016-08-23 | ||||||||||||||||
Sponsor Name:NHS Blood and Transplant. [...] | ||||||||||||||||||
Full Title: TREATT: TRial to EvaluAte Tranexamic acid therapy in Thrombocytopenia A double blind, randomised controlled trial evaluating the safety and efficacy of Tranexamic acid in patients with haematologic... | ||||||||||||||||||
Medical condition: Bleeding secondary to thrombocytopaenia associated to haematological malignancies. | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2017-000552-25 | Sponsor Protocol Number: DS9231-A-U201 | Start Date*: 2017-08-07 | ||||||||||||||||
Sponsor Name:Daiichi Sankyo Inc. | ||||||||||||||||||
Full Title: Evaluation of Safety and Thrombolytic Effect of Ascending Doses of DS-9231 (TS23) in Subjects with Intermediate-Risk (sub-massive) Acute Pulmonary Embolism (PE) | ||||||||||||||||||
Medical condition: DS9231, also known as TS23, is an inhibitor of alpha2-antiplasmin, incrasing plasmin acitivy and enhances fibrinolysis (thrombolysis) and intended to be used for the treatment of patients with Inte... | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: HU (Prematurely Ended) | ||||||||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
